Check out our most popular compounded medications! Get Started
Naproxen 440 mg Slow Release (MEM4) Oral Capsules are a sophisticated pharmaceutical formulation designed to manage pain and inflammation associated with various conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, and menstrual cramps. Each capsule contains 440 mg of the active ingredient naproxen, encapsulated with Methocel E4M, a hydrophilic polymer that ensures a controlled and extended release of the medication. This advanced delivery system allows for a gradual release of naproxen into the bloodstream, maintaining therapeutic levels over a longer duration, thereby reducing the need for frequent dosing and enhancing patient adherence to the treatment regimen.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Naproxen 440 mg Slow Release (MEM4) Oral Capsules are a sophisticated formulation designed to manage pain and inflammation over an extended period. These capsules are compounded using Methocel E4M, a high-viscosity grade hydroxypropyl methylcellulose (HPMC), which acts as a controlled-release polymer. This polymer matrix swells and forms a gel barrier upon contact with gastrointestinal fluids, controlling the rate at which naproxen is released from the capsule. The slow dissolution of the drug ensures a steady release into the bloodstream, maintaining therapeutic levels for a prolonged duration.
The slow release mechanism of Naproxen 440 mg Slow Release (MEM4) Oral Capsules is particularly beneficial for chronic conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal disorders where long-term pain management is required. By providing a consistent release of naproxen, these capsules help in reducing the frequency of dosing, which can enhance patient compliance and convenience. Additionally, the extended release may also minimize the peaks and troughs in drug levels associated with immediate-release formulations, potentially reducing the risk of side effects and improving the overall safety profile of the medication.
For prescribers, it is important to note that the dosing of Naproxen 440 mg Slow Release (MEM4) Oral Capsules may differ from that of immediate-release naproxen due to the modified release characteristics. It is essential to consider the patient's overall medication regimen, including other controlled-release products, to avoid overlapping or duplicative therapy. Monitoring for therapeutic effectiveness and adverse effects is recommended, as with any long-term NSAID therapy. Renal function should be assessed prior to initiating treatment with naproxen, especially in patients with pre-existing renal impairment, as NSAIDs can affect renal prostaglandins and worsen renal function.
Patients should be advised to swallow the capsules whole, without crushing or chewing, to maintain the integrity of the controlled-release system. They should also be informed about the potential side effects of naproxen, such as gastrointestinal irritation, which can be mitigated by taking the medication with food or milk. As with all NSAIDs, there is a risk of cardiovascular and gastrointestinal adverse events, which should be discussed with patients, particularly those with existing heart disease or a history of peptic ulcer disease.
If you have any questions or require further information about Naproxen 440 mg Slow Release (MEM4) Oral Capsules, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support to both patients and healthcare providers to ensure the safe and appropriate use of this medication.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing hormones that cause inflammation and pain in the body. It is commonly used for the treatment of conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. The slow-release formulation of naproxen 440 mg oral capsules, utilizing Methocel E4M, is designed to maintain consistent plasma levels of the drug over an extended period, which can be beneficial in managing chronic pain and inflammatory conditions. However, it is important to consider potential drug interactions when prescribing or taking this medication.
When naproxen is taken concurrently with other NSAIDs, including aspirin, there is an increased risk for gastrointestinal bleeding and ulcers. Patients should generally avoid using multiple NSAIDs concurrently. If low-dose aspirin is used for cardioprotection, it should be taken at least two hours before or after the slow-release naproxen to minimize potential interactions. Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants that can increase gastrointestinal bleeding risk should also be used cautiously with naproxen.
Anticoagulants such as warfarin, heparin, and newer oral anticoagulants (e.g., dabigatran, rivaroxaban) may have their effects potentiated by naproxen, leading to an increased risk of bleeding. Close monitoring of coagulation parameters and clinical vigilance for signs of bleeding is advised when these drugs are used together. Similarly, antiplatelet agents like clopidogrel may have an increased risk of bleeding when taken with naproxen.
Concomitant use of naproxen with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers can reduce their antihypertensive effects. Additionally, naproxen can potentially worsen renal function in patients taking these medications, especially in those with pre-existing renal impairment. Diuretics' effectiveness can also be reduced when taken with naproxen, and this combination may increase the risk of renal failure in susceptible patients.
Patients taking lithium should be aware that naproxen can increase lithium plasma levels, potentially leading to lithium toxicity. Regular monitoring of lithium levels is recommended when initiating or changing the dosage of naproxen in these patients. Drugs that are known to cause hyperkalemia, such as potassium-sparing diuretics, potassium supplements, or ACE inhibitors, may have their effects exacerbated by naproxen, necessitating monitoring of serum potassium levels.
Concurrent use of naproxen with methotrexate can lead to increased methotrexate toxicity due to reduced renal clearance. Patients on methotrexate should be closely monitored for toxicity, especially when starting or changing the dose of naproxen. Cytochrome P450 2C9 substrates, such as warfarin, may have altered effects when taken with naproxen, as naproxen can inhibit this enzyme, potentially leading to increased plasma levels of these drugs.
It is important for patients and prescribers to be aware of these potential interactions and to manage them appropriately. This may involve monitoring drug levels, adjusting doses, or choosing alternative therapies. If you have any questions or concerns regarding the use of naproxen 440 mg slow-release oral capsules or potential drug interactions, please reach out to us at Bayview Pharmacy for further assistance.
The Naproxen 440 mg Slow Release (MEM4) Oral Capsules are a sophisticated formulation designed to manage pain and inflammation over an extended period. The key to this formulation's effectiveness lies in the use of Methocel E4M, a hydrophilic polymer that swells upon contact with gastric fluids, forming a gel matrix. This gel matrix creates a barrier that controls the rate at which the active ingredient, naproxen, is released from the capsule and absorbed into the bloodstream.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the production of prostaglandins, substances in the body responsible for pain, fever, and inflammation. By reducing the levels of prostaglandins, naproxen effectively alleviates symptoms associated with various inflammatory conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.
The incorporation of Methocel E4M in the capsule formulation ensures that the release of naproxen is not immediate but occurs gradually over time. This slow release mechanism allows for a more consistent serum concentration of the drug, which not only prolongs its analgesic and anti-inflammatory effects but also minimizes the potential for side effects commonly associated with peak plasma levels of NSAIDs. As a result, patients may experience relief from their symptoms without the need for frequent dosing, which can enhance adherence to the medication regimen.
For prescribers, it is important to note that the slow release formulation of naproxen may differ in onset of action compared to immediate-release forms. Therefore, it may not be suitable for the treatment of acute pain where rapid onset is required. However, for chronic conditions requiring long-term management, this formulation can be an excellent choice to maintain therapeutic drug levels and improve patient quality of life.
Patients should be advised that while the slow release formulation is designed to reduce dosing frequency, it is crucial to adhere to the prescribed dosing schedule and not to crush or chew the capsules, as this would disrupt the controlled-release mechanism. Additionally, as with all NSAIDs, patients should be monitored for signs of gastrointestinal, cardiovascular, or renal side effects, and the use of Naproxen 440 mg Slow Release (MEM4) Oral Capsules should be under the guidance of a healthcare professional.
If you have any questions about the Naproxen 440 mg Slow Release (MEM4) Oral Capsules or would like more information on how this formulation can benefit your patients, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the support and answers you need to ensure the best possible outcomes for your patients.
Naproxen 440 mg Slow Release (MEM4) Oral Capsules are a form of pain reliever and anti-inflammatory medication, which uses a controlled-release system to gradually release the drug over time. It is designed to maintain steady therapeutic effects and decrease the need for frequent dosing.
These capsules are formulated with Methocel E4M, a controlled-release polymer that allows the active ingredient, naproxen, to be released slowly into the body. This ensures a prolonged therapeutic effect and can help prevent the peaks and valleys in drug concentration that might occur with immediate-release formulations.
The slow-release formulation offers several benefits, including sustained relief from symptoms, reduced frequency of doses, and potentially fewer side effects since the medication is released gradually rather than all at once. This can also improve patient compliance with their treatment plan.
No, you should not break, chew, or crush the Naproxen Slow Release capsules. Doing so would interfere with the controlled-release mechanism and could result in the release of the entire dose at once, increasing the risk of side effects.
The dosing schedule for Naproxen Slow Release capsules can vary based on individual patient needs and medical advice. Always follow the dosing instructions provided by your healthcare professional, as they will be tailored to your specific condition and treatment plan.
Yes, the capsules should be stored at room temperature, away from excessive heat, moisture, and light. Keep the bottle tightly closed when not in use and keep out of reach of children.
If you miss a dose, take it as soon as you remember. However, if it is near the time of the next scheduled dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.
It is generally not recommended to consume alcohol while taking any medication, including Naproxen Slow Release capsules, as alcohol can increase the risk of stomach ulcers and bleeding associated with naproxen.
There are no specific dietary restrictions while taking Naproxen Slow Release capsules, but it is generally advised to take them with food or milk to minimize gastrointestinal discomfort. Discuss with your healthcare provider if you have any dietary concerns.
Individuals with a known allergy to naproxen or any component of the formulation should avoid these capsules. Additionally, patients with a history of severe heart, liver, or kidney disease, gastrointestinal bleeding or ulcers, or clotting disorders should consult with their healthcare provider before use. Pregnant or breastfeeding women should also seek medical advice prior to taking naproxen.
Some medications may interact with Naproxen Slow Release capsules, affecting how it works or increasing the risk of side effects. Always inform your healthcare provider about all the medications and supplements you are taking to ensure that the naproxen is compatible with them.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
